{"protocolSection":{"identificationModule":{"nctId":"NCT02963922","orgStudyIdInfo":{"id":"NN8022-4272"},"secondaryIdInfos":[{"id":"U1111-1177-4903","type":"OTHER","domain":"World Health Organization (WHO)"},{"id":"2015-005619-33","type":"EUDRACT_NUMBER"},{"id":"2015","type":"NIH","link":"https://reporter.nih.gov/quickSearch/2015"}],"organization":{"fullName":"Novo Nordisk A/S","class":"INDUSTRY"},"briefTitle":"Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin","officialTitle":"Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin","acronym":"SCALE™ Insulin"},"statusModule":{"statusVerifiedDate":"2020-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-02-06","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-09-10","type":"ACTUAL"},"completionDateStruct":{"date":"2018-09-25","type":"ACTUAL"},"studyFirstSubmitDate":"2016-11-10","studyFirstSubmitQcDate":"2016-11-10","studyFirstPostDateStruct":{"date":"2016-11-15","type":"ESTIMATED"},"resultsFirstSubmitDate":"2019-09-04","resultsFirstSubmitQcDate":"2019-11-08","resultsFirstPostDateStruct":{"date":"2019-11-27","type":"ACTUAL"},"lastUpdateSubmitDate":"2020-03-13","lastUpdatePostDateStruct":{"date":"2020-03-30","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Novo Nordisk A/S","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This trial is conducted globally. The aim of this trial is to investigate effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin."},"conditionsModule":{"conditions":["Metabolism and Nutrition Disorder","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":396,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"liraglutide 3.0 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Liraglutide 3.0 mg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"Liraglutide 3.0 mg","description":"Injected subcutaneously (s.c., under the skin) once daily","armGroupLabels":["liraglutide 3.0 mg"]},{"type":"DRUG","name":"Placebo","description":"Injected subcutaneously (s.c., under the skin) once daily","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change in Body Weight (%)","description":"Change in body weight from baseline (week 0) to week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for adverse events \\[AEs\\]) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).","timeFrame":"Week 0, week 56"},{"measure":"Participants Losing at Least 5% of Baseline Body Weight","description":"The estimated percentage of participants losing at least 5% of baseline (week 0) body weight at week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for adverse events \\[AEs\\]) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).","timeFrame":"Week 56"}],"secondaryOutcomes":[{"measure":"Participants Losing More Than 10% of Baseline Body Weight at Week 56","description":"The estimated percentage of participants losing more than 10% of baseline (week 0) body weight at week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for adverse events \\[AEs\\]) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).","timeFrame":"Week 56"},{"measure":"Change in Waist Circumference","description":"Change in waist circumference from baseline (week 0) to week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for AEs) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).","timeFrame":"Week 0, week 56"},{"measure":"Change in HbA1c","description":"Change in glycosylated haemoglobin (HbA1c) from baseline (week 0) to week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for AEs) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).","timeFrame":"Week 0, week 56"},{"measure":"Change in FPG","description":"Change in fasting plasma glucose (FPG) from baseline (week 0) to week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for AEs) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).","timeFrame":"Week 0, week 56"},{"measure":"Change in Short Form-36 (SF-36) v2.0 Acute, Physical Functioning Score","description":"SF-36 is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline (week 0) in SF-36 physical functioning score was presented based on in-trial data and on-drug data. A positive change score indicates an improvement since baseline.","timeFrame":"Week 0, week 56"},{"measure":"Change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT), Physical Function Domain (5-items) Score","description":"Change in IWQoL-Lite for CT physical function domain (5-items) score. IWQoL-Lite for CT is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. The endpoint was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for AEs) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).","timeFrame":"Week 0, week 56"},{"measure":"Change in Total Daily Insulin Dose (U)","description":"Change in total daily insulin dose from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 0, week 56"},{"measure":"Change in Total Daily Basal Insulin Dose (% of Pre-trial Dose in U)","description":"Change in total daily basal insulin dose from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 0, week 56"},{"measure":"Change in Total Daily Basal Insulin Dose (U/kg)","description":"Change in total daily basal insulin dose from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 0, week 56"},{"measure":"Change in Total Daily Insulin Dose (U/kg)","description":"Change in total daily insulin dose from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 0, week 56"},{"measure":"Change in 7-point SMPG Profile Mean Daytime Glucose Value","description":"Participants measured plasma glucose values using the blood glucose meter at 7 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner and at bedtime. Change from baseline (week 0) to week 56 in 7-point self-measured plasma glucose (SMPG) profile mean daytime glucose value was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 0, week 56"},{"measure":"Change in sBP and dBP","description":"Change in systolic blood pressure (sBP) and diastolic blood pressure (dBP) from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 0, week 56"},{"measure":"Change in Lipids -Total Cholesterol, HDL, LDL, VLDL, Triglycerides and FFA","description":"Change in total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, very low density lipoprotein (VLDL) cholesterol, triglycerides and free fatty acids (FFA) from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 0, week 56"},{"measure":"Change in SF-36: Sub-domains","description":"SF-36 is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in the sub-domain scores was presented based on in-trial data. A positive change score indicates an improvement since baseline. Results are presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 0, week 56"},{"measure":"Change in SF-36: Physical Component Summary (PCS)","description":"Change in short form 36 v2.0 acute domain physical component summary (PCS) from baseline (week 0) to week 56 was presented based on in-trial data. SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. It consists of 2 component summary measures that further summarize 8 health domain scales. The physical component summary (PCS) measure is derived from domain scales of physical functioning, role-physical, bodily pain, and general health. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. A positive change score indicates an improvement since baseline.","timeFrame":"Week 0, week 56"},{"measure":"Change in SF-36: Mental Component Summary (MCS)","description":"Change in short form 36 v2.0 acute domain mental component summary (MCS) from baseline (week 0) to week 56 was presented based on in-trial data. SF- 36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The mental component summary (MCS) measure is derived from domain scales of vitality, social functioning, role emotional and mental health. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. A positive change score indicates an improvement since baseline.","timeFrame":"Week 0, week 56"},{"measure":"Change in IWQoL-Lite for CT: Pain/Discomfort Domain Score","description":"Change in IWQoL-Lite for CT pain and discomfort domain from baseline (week 0) to week 56 was presented based on in-trial data. IWQoL-Lite for CT is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 0, week 56"},{"measure":"Change in IWQoL-Lite for CT: Psychosocial Domain Score","description":"Change in IWQoL-Lite for CT psychosocial domain from baseline (week 0) to week 56 was presented based on in-trial data. IWQoL-Lite for CT is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 0, week 56"},{"measure":"Change in IWQoL-Lite for CT: Total Score","description":"Change in IWQoL-Lite for CT total score from baseline (week 0) to week 56 was presented based on in-trial data. IWQoL-Lite for CT is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 0, week 56"},{"measure":"Weight Related Sign and Symptom (WRSS) Measure, Categorical Responses","description":"The WRSS measure is a questionnaire under development. The version applied in this study has 10 items that measure the presence and bothersomeness of 10 weight-related symptoms. Each item has a categorical part with answers on the following 5 possible levels: 'Never/Almost never', 'Rarely', 'Sometimes', 'Often' and 'Almost always/Always'. Number of participants in each category at baseline (week 0) and week 56 was presented. Scoring algorithm was not available prior to database lock and therefore it was decided and documented in the statistical analysis plan that WRSS total score was not to be calculated and analyzed.","timeFrame":"Week 0, week 56"},{"measure":"Participants Who Achieved (Yes/no): HbA1c <7% and Weight Loss ≥5%","description":"Percentage of participants who achieved HbA1c \\<7% and weight loss ≥5% from baseline at week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 56"},{"measure":"Participants Who Achieved (Yes/no): HbA1c <7%, Weight Loss ≥5% and no Documented Symptomatic Hypoglycaemia","description":"Percentage of participants who achieved HbA1c \\<7%, weight loss ≥5% from baseline and no documented symptomatic hypoglycaemia at week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 56"},{"measure":"Participants Who Achieved (Yes/no): ≥4.3 T-score Points Increase From Baseline in SF-36 Acute Physical Functioning Score","description":"Percentage of participants who achieved ≥4.3 T-score points increase from baseline in SF-36 acute physical functioning score at week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 56"},{"measure":"Participants Who Achieved (Yes/no): ≥3.8 T-score Points Increase From Baseline in SF-36 Acute PCS","description":"Percentage of participants who achieved ≥3.8 T-score points increase from baseline in SF-36 acute PCS at week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 56"},{"measure":"Participants Who Achieved (Yes/no): ≥4.6 T-score Points Increase From Baseline in SF-36 Acute MCS","description":"Percentage of participants who achieved ≥4.6 T-score points increase from baseline in SF-36 acute MCS at week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 56"},{"measure":"Responder Definition Value for IWQoL-Lite for CT Physical Function Domain Score","description":"Percentage of participants who achieve responder definition value for IWQoL-Lite for CT physical function domain score was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 56"},{"measure":"Adverse Events (AEs)","description":"An AE was defined as any untoward medical occurrence in a participant administered a medicinal product, and which does not necessarily have a causal relationship with this treatment. Number of AEs from randomisation to until the end of the post-treatment follow-up period (30 days). Results based on in-trial data was presented. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 0 to week 56 + 30 days"},{"measure":"Number of Hypoglycaemic Episodes","description":"Number of hypoglycaemic episodes was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 0 to week 56 + 30 days"},{"measure":"Change in Physical Examination","description":"Physical examination parameters are categorised as abdomen; gastrointestinal system; cardiovascular system; central and peripheral nervous system; general appearance; head, eyes, ears, nose, throat (ENT) and neck; lymph node palpation; musculoskeletal system; respiratory system; skin and thyroid gland. The number of participants assessed as normal, abnormal not clinically significant (NCS) and abnormal clinically significant (CS) at baseline (week -1) and week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week -1, week 56"},{"measure":"Change in Resting Pulse","description":"Change from baseline (week -1) to week 56 in resting pulse was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week -1, week 56"},{"measure":"Change in Electrocardiogram (ECG)","description":"The ECGs were interpreted by the investigator at baseline (week -1) and week 56 and categorised as normal, abnormal NCS or abnormal CS. Number of participants in each ECG category at baseline and week 56 were presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week -1, week 56"},{"measure":"Change in Laboratory Measurements (Haematology) - Haemoglobin","description":"Change from baseline (week 0) to week 56 in haemoglobin was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 0, week 56"},{"measure":"Change in Laboratory Measurements (Haematology) - Haematocrit","description":"Change from baseline (week 0) to week 56 in Haematocrit was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 0, week 56"},{"measure":"Change in Laboratory Measurements (Haematology) - Erythrocytes","description":"Change from baseline (week 0) to week 56 in erythrocytes was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 0, week 56"},{"measure":"Change in Laboratory Measurements (Haematology) - Thrombocytes, Leukocytes","description":"Change from baseline (week 0) to week 56 in thrombocytes and leukocytes was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 0, week 56"},{"measure":"Change in Laboratory Parameters (Biochemistry) - Albumin","description":"Change from baseline (week 0) to week 56 in albumin was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 0, week 56"},{"measure":"Change in Laboratory Parameters (Biochemistry) - Alkaline Phosphatase, Alanine Aminotransferase, Amylase, Aspartate Aminotransferase and Lipase","description":"Change from baseline (week 0) to week 56 in alkaline phosphatase, alanine aminotransferase, amylase, aspartate aminotransferase and lipase was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 0, week 56"},{"measure":"Change in Laboratory Parameters (Biochemistry) - Bicarbonate, Total Calcium, Potassium, Sodium and Urea","description":"Change from baseline (week 0) to week 56 in bicarbonate, total calcium, potassium, sodium and urea was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 0, week 56"},{"measure":"Change in Laboratory Parameters (Biochemistry) - Total Bilirubin and Creatinine","description":"Change from baseline (week 0) to week 56 in total bilirubin and creatinine was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 0, week 56"},{"measure":"Change in Laboratory Parameters (Biochemistry) - High Sensitive C-reactive Protein","description":"Change from baseline (week 0) to week 56 in high sensitive C-reactive protein was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 0, week 56"},{"measure":"Change in Laboratory Parameters (Biochemistry) - eGFR","description":"Change from baseline (week 0) to week 56 in estimated GFR serum using Modification of Diet in Renal Disease (MDRD) formula was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 0, week 56"},{"measure":"Change in Laboratory Parameters (Biochemistry) - Uric Acid","description":"Change from baseline (week 0) to week 56 in uric acid was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 0, week 56"},{"measure":"Change in Laboratory Parameters (Biochemistry) - Calcitonin","description":"Change from baseline (week 0) to week 56 in calcitonin was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 0, week 56"},{"measure":"Change in Laboratory Parameters (Biochemistry) - Thyroid Stimulating Hormone","description":"Change from baseline (week 0) to week 56 in thyroid stimulating hormone was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","timeFrame":"Week 0, week 56"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria: - Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial - Diagnosed with type 2 diabetes mellitus - Treatment with up to 2 OADs (oral anti-diabetic) (metformin, glitazone, SGLT-2 inhibitor (sodium-glucose cotransporter-2 inhibitors) or sulphonylurea) - Stable treatment with basal insulin according to its label (no requirement of minimum or maximum dose) for at least 90 days prior to screening, as judged by the investigator - HbA1c (glycosylated haemoglobin) 6.0-10.0% (both inclusive) - BMI (body mass index) equal to or above 27 kg/m\\^2 - Age at least 18 years at the time of signing informed consent Exclusion Criteria: - Diagnosis of type 1 diabetes - Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question 8 (see Section 8.2.3) - Recurrent severe hypoglycaemic episodes within the last year as judged by the investigator - Unable or unwilling to perform self-monitoring of plasma glucose according to the protocol and to keep a diabetes diary - Treatment with any hypoglycaemic medications other than OADs and basal insulin within the past 90 days prior to screening - Treatment with a DPP-IV (dipeptidyl peptidase-4) inhibitor within the past 90 days prior to screening - Recent history of cardiovascular disease (myocardial infarction or stroke within the past 6 months), severe congestive heart failure (NYHA class III, IV), or second degree or greater heart block - Personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2) - Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method (adequate contraceptive measure as required by local regulation or practice) - For Germany: Only highly effective methods of birth control are accepted (i.e. one that results in less than 1% per year failure rate when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine device), or sexual abstinence or vasectomised partner - Use in past 90 days of medications known to induce significant weight loss (e.g., prescription weight loss medications) or weight gain (e.g., chronic use of oral steroids, second generation antipsychotics) - History of pancreatitis (acute or chronic) - History of major depressive disorder within the past 2 years - Any lifetime history of a suicide attempt - Inadequately treated blood pressure defined as Grade 3 hypertension or higher (Systolic above or equal to 180 mmHg or diastolic above or equal to110 mmHg). - History of malignancy (except for non-melanoma skin cancer) within the past 5 years","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Novo Nordisk Investigational Site","city":"Birmingham","state":"Alabama","zip":"35294","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"Novo Nordisk Investigational Site","city":"Concord","state":"California","zip":"94520","country":"United States","geoPoint":{"lat":37.97798,"lon":-122.03107}},{"facility":"Novo Nordisk Investigational Site","city":"Fresno","state":"California","zip":"93720","country":"United States","geoPoint":{"lat":36.74773,"lon":-119.77237}},{"facility":"Novo Nordisk Investigational Site","city":"Jacksonville","state":"Florida","zip":"32205","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Novo Nordisk Investigational Site","city":"Plantation","state":"Florida","zip":"33324","country":"United States","geoPoint":{"lat":26.13421,"lon":-80.23184}},{"facility":"Novo Nordisk Investigational Site","city":"Roswell","state":"Georgia","zip":"30076","country":"United States","geoPoint":{"lat":34.02316,"lon":-84.36159}},{"facility":"Novo Nordisk Investigational Site","city":"Honolulu","state":"Hawaii","zip":"96814","country":"United States","geoPoint":{"lat":21.30694,"lon":-157.85833}},{"facility":"Novo Nordisk Investigational Site","city":"Chicago","state":"Illinois","zip":"60607","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Novo Nordisk Investigational Site","city":"Louisville","state":"Kentucky","zip":"40213","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"Novo Nordisk Investigational Site","city":"North Dartmouth","state":"Massachusetts","zip":"02747","country":"United States","geoPoint":{"lat":41.63899,"lon":-70.97032}},{"facility":"Novo Nordisk Investigational Site","city":"Minneapolis","state":"Minnesota","zip":"55416","country":"United States","geoPoint":{"lat":44.97997,"lon":-93.26384}},{"facility":"Novo Nordisk Investigational Site","city":"Butte","state":"Montana","zip":"59701","country":"United States","geoPoint":{"lat":46.00382,"lon":-112.53474}},{"facility":"Novo Nordisk Investigational Site","city":"Albany","state":"New York","zip":"12206","country":"United States","geoPoint":{"lat":42.65258,"lon":-73.75623}},{"facility":"Novo Nordisk Investigational Site","city":"Wilmington","state":"North Carolina","zip":"28401","country":"United States","geoPoint":{"lat":34.23556,"lon":-77.94604}},{"facility":"Novo Nordisk Investigational Site","city":"Austin","state":"Texas","zip":"78731","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Novo Nordisk Investigational Site","city":"Austin","state":"Texas","zip":"78749","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Novo Nordisk Investigational Site","city":"Dallas","state":"Texas","zip":"75230","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Novo Nordisk Investigational Site","city":"Dallas","state":"Texas","zip":"75231","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Novo Nordisk Investigational Site","city":"Winchester","state":"Virginia","zip":"22601-3834","country":"United States","geoPoint":{"lat":39.18566,"lon":-78.16333}},{"facility":"Novo Nordisk Investigational Site","city":"Calgary","state":"Alberta","zip":"T2V 4J2","country":"Canada","geoPoint":{"lat":51.05011,"lon":-114.08529}},{"facility":"Novo Nordisk Investigational Site","city":"Edmonton","state":"Alberta","zip":"T6H 2L4","country":"Canada","geoPoint":{"lat":53.55014,"lon":-113.46871}},{"facility":"Novo Nordisk Investigational Site","city":"Halifax","state":"Nova Scotia","zip":"B3H 2Y9","country":"Canada","geoPoint":{"lat":44.64269,"lon":-63.57688}},{"facility":"Novo Nordisk Investigational Site","city":"Hamilton","state":"Ontario","zip":"L8L 5G8","country":"Canada","geoPoint":{"lat":43.25011,"lon":-79.84963}},{"facility":"Novo Nordisk Investigational Site","city":"London","state":"Ontario","zip":"N6A 5B7","country":"Canada","geoPoint":{"lat":42.98339,"lon":-81.23304}},{"facility":"Novo Nordisk Investigational Site","city":"Toronto","state":"Ontario","zip":"M6G 1M2","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Novo Nordisk Investigational Site","city":"Waterloo","state":"Ontario","zip":"N2J 1C4","country":"Canada","geoPoint":{"lat":43.4668,"lon":-80.51639}},{"facility":"Novo Nordisk Investigational Site","city":"Québec","zip":"G1V 4G5","country":"Canada","geoPoint":{"lat":46.81228,"lon":-71.21454}},{"facility":"Novo Nordisk Investigational Site","city":"Dresden","zip":"01307","country":"Germany","geoPoint":{"lat":51.05089,"lon":13.73832}},{"facility":"Novo Nordisk Investigational Site","city":"Essen","zip":"45219","country":"Germany","geoPoint":{"lat":51.45657,"lon":7.01228}},{"facility":"Novo Nordisk Investigational Site","city":"Falkensee","zip":"14612","country":"Germany","geoPoint":{"lat":52.56014,"lon":13.0927}},{"facility":"Novo Nordisk Investigational Site","city":"Hamburg","zip":"22607","country":"Germany","geoPoint":{"lat":53.55073,"lon":9.99302}},{"facility":"Novo Nordisk Investigational Site","city":"Leipzig","zip":"04103","country":"Germany","geoPoint":{"lat":51.33962,"lon":12.37129}},{"facility":"Novo Nordisk Investigational Site","city":"Münster","zip":"48145","country":"Germany","geoPoint":{"lat":51.96236,"lon":7.62571}},{"facility":"Novo Nordisk Investigational Site","city":"Rehlingen-Siersburg","zip":"66780","country":"Germany","geoPoint":{"lat":49.37565,"lon":6.68439}},{"facility":"Novo Nordisk Investigational Site","city":"Saint Ingbert-Oberwürzbach","zip":"66386","country":"Germany"},{"facility":"Novo Nordisk Investigational Site","city":"Haifa","zip":"35152","country":"Israel","geoPoint":{"lat":32.81303,"lon":34.99928}},{"facility":"Novo Nordisk Investigational Site","city":"Jerusalem","zip":"91120","country":"Israel","geoPoint":{"lat":31.76904,"lon":35.21633}},{"facility":"Novo Nordisk Investigational Site","city":"Kfar Saba","zip":"44281","country":"Israel","geoPoint":{"lat":32.175,"lon":34.90694}},{"facility":"Novo Nordisk Investigational Site","city":"Petah Tikva","zip":"49372","country":"Israel","geoPoint":{"lat":32.0888,"lon":34.88666}},{"facility":"Novo Nordisk Investigational Site","city":"Tel Aviv","zip":"64239","country":"Israel","geoPoint":{"lat":32.08088,"lon":34.78057}},{"facility":"Novo Nordisk Investigational Site","city":"Tel Litwinsky","zip":"52621","country":"Israel","geoPoint":{"lat":32.05096,"lon":34.84588}},{"facility":"Novo Nordisk Investigational Site","city":"Bologna","zip":"40138","country":"Italy","geoPoint":{"lat":44.49381,"lon":11.33875}},{"facility":"Novo Nordisk Investigational Site","city":"Naples","zip":"80131","country":"Italy","geoPoint":{"lat":40.85216,"lon":14.26811}},{"facility":"Novo Nordisk Investigational Site","city":"Palermo","zip":"90127","country":"Italy","geoPoint":{"lat":38.1166,"lon":13.3636}},{"facility":"Novo Nordisk Investigational Site","city":"Rome","zip":"00168","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"Novo Nordisk Investigational Site","city":"Guadalajara","state":"Jalisco","zip":"44600","country":"Mexico","geoPoint":{"lat":20.67738,"lon":-103.34749}},{"facility":"Novo Nordisk Investigational Site","city":"Monterrey","state":"Nuevo León","zip":"64620","country":"Mexico","geoPoint":{"lat":25.68435,"lon":-100.31721}},{"facility":"Novo Nordisk Investigational Site","city":"Ankara","zip":"06500","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Novo Nordisk Investigational Site","city":"Antalya","zip":"07058","country":"Turkey (Türkiye)","geoPoint":{"lat":36.90812,"lon":30.69556}},{"facility":"Novo Nordisk Investigational Site","city":"Istanbul","zip":"34096","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Novo Nordisk Investigational Site","city":"Istanbul","zip":"34303","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Novo Nordisk Investigational Site","city":"Istanbul","zip":"34371","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Novo Nordisk Investigational Site","city":"Istanbul","zip":"34890","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Novo Nordisk Investigational Site","city":"Izmir","zip":"35340","country":"Turkey (Türkiye)","geoPoint":{"lat":38.41273,"lon":27.13838}}]},"referencesModule":{"references":[{"pmid":"32139381","type":"RESULT","citation":"Garvey WT, Birkenfeld AL, Dicker D, Mingrone G, Pedersen SD, Satylganova A, Skovgaard D, Sugimoto D, Jensen C, Mosenzon O. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial. Diabetes Care. 2020 May;43(5):1085-1093. doi: 10.2337/dc19-1745. Epub 2020 Mar 5."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"According to the Novo Nordisk disclosure commitment on novonordisk-trials.com"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Participants were randomised in a 1:1 manner to receive either liraglutide or placebo as an adjunct to a reduced-calorie diet and increased physical activity as part of a comprehensive lifestyle intervention program.","recruitmentDetails":"The trial was conducted at 53 sites in Canada (7), Germany (7), Israel (6), Italy (4), Mexico (2), Turkey (7) and United States (20).","groups":[{"id":"FG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 milligrams (mg) liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"FG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"198"},{"groupId":"FG001","numSubjects":"198"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"166"},{"groupId":"FG001","numSubjects":"168"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"30"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Protocol deviation","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"14"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"BG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"198"},{"groupId":"BG001","value":"198"},{"groupId":"BG002","value":"396"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"55.9","spread":"11.3"},{"groupId":"BG001","value":"57.6","spread":"10.4"},{"groupId":"BG002","value":"56.8","spread":"10.9"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"108"},{"groupId":"BG001","value":"99"},{"groupId":"BG002","value":"207"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"90"},{"groupId":"BG001","value":"99"},{"groupId":"BG002","value":"189"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"43"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"72"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"155"},{"groupId":"BG001","value":"169"},{"groupId":"BG002","value":"324"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race/Ethnicity, Customized","description":"Race is presented.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"8"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"28"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"174"},{"groupId":"BG001","value":"180"},{"groupId":"BG002","value":"354"}]},{"title":"Other","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]}]}]},{"title":"Body weight","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Kilograms (kg)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"100.6","spread":"20.8"},{"groupId":"BG001","value":"98.9","spread":"19.9"},{"groupId":"BG002","value":"99.7","spread":"20.3"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Body Weight (%)","description":"Change in body weight from baseline (week 0) to week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for adverse events \\[AEs\\]) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).","populationDescription":"Full analysis set included all randomised participants. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percentage change","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"198"}]}],"classes":[{"title":"In-trial observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"191"},{"groupId":"OG001","value":"193"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.0","spread":"6.0"},{"groupId":"OG001","value":"-1.5","spread":"5.4"}]}]},{"title":"On-drug observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"168"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.5","spread":"5.8"},{"groupId":"OG001","value":"-1.7","spread":"5.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Analysis of in-trial data with missing observations imputed from the placebo arm based on a jump to reference multiple (x100) imputation approach. Week 56 responses were analysed using an analysis of covariance model with treatment, body mass index (BMI) groups and sex as factors and baseline body weight as covariate.","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"The treatment policy estimand evaluated the treatment effect (liraglutide 3.0 mg vs placebo) at week 56 for all randomised participants regardless of premature discontinuation of trial product.","pValue":"< .0001","statisticalMethod":"ANCOVA","paramType":"Treatment difference","paramValue":"-4.32","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.48","ciUpperLimit":"-3.16","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.59","estimateComment":"Liraglutide 3.0 mg - placebo"},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis of on-drug before first drug discontinuation date using a mixed model for repeated measurements with treatment, BMI groups and sex as factors and baseline body weight as covariate, all nested within visit.","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"The hypothetical estimand evaluated the treatment effect (liraglutide 3.0 mg vs placebo) for all randomised participants assuming that all participants remained on trial product (on-treatment principle).","pValue":"< .0001","statisticalMethod":"MMRM","paramType":"Treatment difference","paramValue":"-5.10","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.30","ciUpperLimit":"-3.91","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.61","estimateComment":"Liraglutide 3.0 mg - placebo"}]},{"type":"PRIMARY","title":"Participants Losing at Least 5% of Baseline Body Weight","description":"The estimated percentage of participants losing at least 5% of baseline (week 0) body weight at week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for adverse events \\[AEs\\]) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).","populationDescription":"Full analysis set included all randomised participants. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"198"}]}],"classes":[{"title":"In-trial observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"191"},{"groupId":"OG001","value":"193"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"51.80"},{"groupId":"OG001","value":"23.98"}]}]},{"title":"On-drug observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"56.92"},{"groupId":"OG001","value":"21.83"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Analysis of in-trial data with missing observations imputed from the placebo arm based on a jump to reference multiple (x100) imputation approach. Week 56 responses were analysed using a logistic regression model with treatment, BMI groups and sex as factors and baseline body weight as covariate.","nonInferiorityType":"SUPERIORITY","pValue":"<.0001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"3.41","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.19","ciUpperLimit":"5.31","estimateComment":"Liraglutide 3.0 mg/Placebo"},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis of on-drug before first drug discontinuation date using a mixed model for repeated measurements with treatment, BMI groups and sex as factors and baseline body weight as covariate, all nested within visit. The MMRM was used to classify responders and analysed with a logistic regression with treatment as the only factor.","nonInferiorityType":"SUPERIORITY","pValue":"<.0001","statisticalMethod":"Mixed model for repeated measurements","paramType":"Odds Ratio (OR)","paramValue":"4.73","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.04","ciUpperLimit":"7.36","estimateComment":"Liraglutide 3.0 mg/Placebo"}]},{"type":"SECONDARY","title":"Participants Losing More Than 10% of Baseline Body Weight at Week 56","description":"The estimated percentage of participants losing more than 10% of baseline (week 0) body weight at week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for adverse events \\[AEs\\]) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).","populationDescription":"Full analysis set included all randomised participants. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"198"}]}],"classes":[{"title":"In-trial observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"191"},{"groupId":"OG001","value":"193"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.77"},{"groupId":"OG001","value":"6.55"}]}]},{"title":"On-drug observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.56"},{"groupId":"OG001","value":"5.58"}]}]}]},{"type":"SECONDARY","title":"Change in Waist Circumference","description":"Change in waist circumference from baseline (week 0) to week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for AEs) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).","populationDescription":"Full analysis set included all randomised participants. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Centimeters (cm)","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"198"}]}],"classes":[{"title":"In-trial observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"189"},{"groupId":"OG001","value":"193"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.40","spread":"6.06"},{"groupId":"OG001","value":"-2.60","spread":"5.72"}]}]},{"title":"On-drug observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"168"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.71","spread":"6.05"},{"groupId":"OG001","value":"-2.78","spread":"5.63"}]}]}]},{"type":"SECONDARY","title":"Change in HbA1c","description":"Change in glycosylated haemoglobin (HbA1c) from baseline (week 0) to week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for AEs) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).","populationDescription":"Full analysis set included all randomised participants. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percentage of HbA1c","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"198"}]}],"classes":[{"title":"In-trial observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"188"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"1.2"},{"groupId":"OG001","value":"-0.5","spread":"1.2"}]}]},{"title":"On-drug observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"164"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"1.1"},{"groupId":"OG001","value":"-0.7","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Change in FPG","description":"Change in fasting plasma glucose (FPG) from baseline (week 0) to week 56 was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for AEs) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).","populationDescription":"Full analysis set included all randomised participants. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Millimoles per liter (mmol/L)","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"198"}]}],"classes":[{"title":"In-trial observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"188"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.91","spread":"3.13"},{"groupId":"OG001","value":"-0.68","spread":"3.04"}]}]},{"title":"On-drug observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"165"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.05","spread":"3.08"},{"groupId":"OG001","value":"-0.96","spread":"2.68"}]}]}]},{"type":"SECONDARY","title":"Change in Short Form-36 (SF-36) v2.0 Acute, Physical Functioning Score","description":"SF-36 is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline (week 0) in SF-36 physical functioning score was presented based on in-trial data and on-drug data. A positive change score indicates an improvement since baseline.","populationDescription":"Full analysis set included all randomised participants. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Score on a scale","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"198"}]}],"classes":[{"title":"In-trial observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"7.9"},{"groupId":"OG001","value":"2.6","spread":"7.3"}]}]},{"title":"On-drug observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"161"},{"groupId":"OG001","value":"167"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"7.8"},{"groupId":"OG001","value":"2.5","spread":"7.1"}]}]}]},{"type":"SECONDARY","title":"Change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT), Physical Function Domain (5-items) Score","description":"Change in IWQoL-Lite for CT physical function domain (5-items) score. IWQoL-Lite for CT is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. The endpoint was presented based on in-trial data and on-drug data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which participants are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for AEs) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs).","populationDescription":"Full analysis set included all randomised participants. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Score on a scale","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"198"}]}],"classes":[{"title":"In-trial observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":"22.5"},{"groupId":"OG001","value":"6.8","spread":"21.5"}]}]},{"title":"On-drug observation period","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"161"},{"groupId":"OG001","value":"167"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":"20.9"},{"groupId":"OG001","value":"6.5","spread":"21.8"}]}]}]},{"type":"SECONDARY","title":"Change in Total Daily Insulin Dose (U)","description":"Change in total daily insulin dose from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"Full analysis set included all randomised participants. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Units of insulin dose (U)","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"198"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":"30"},{"groupId":"OG001","value":"18","spread":"38"}]}]}]},{"type":"SECONDARY","title":"Change in Total Daily Basal Insulin Dose (% of Pre-trial Dose in U)","description":"Change in total daily basal insulin dose from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"Full analysis set included all randomised participants. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percentage change","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"198"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":"121"},{"groupId":"OG001","value":"64","spread":"139"}]}]}]},{"type":"SECONDARY","title":"Change in Total Daily Basal Insulin Dose (U/kg)","description":"Change in total daily basal insulin dose from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"Full analysis set included all randomised participants. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Units of insulin dose per kilogram(U/kg)","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"198"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.33"},{"groupId":"OG001","value":"0.15","spread":"0.30"}]}]}]},{"type":"SECONDARY","title":"Change in Total Daily Insulin Dose (U/kg)","description":"Change in total daily insulin dose from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"Full analysis set included all randomised participants. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"U/kg","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"198"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.33"},{"groupId":"OG001","value":"0.18","spread":"0.37"}]}]}]},{"type":"SECONDARY","title":"Change in 7-point SMPG Profile Mean Daytime Glucose Value","description":"Participants measured plasma glucose values using the blood glucose meter at 7 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner and at bedtime. Change from baseline (week 0) to week 56 in 7-point self-measured plasma glucose (SMPG) profile mean daytime glucose value was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"Full analysis set included all randomised participants. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"198"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"2.6"},{"groupId":"OG001","value":"-1.6","spread":"2.8"}]}]}]},{"type":"SECONDARY","title":"Change in sBP and dBP","description":"Change in systolic blood pressure (sBP) and diastolic blood pressure (dBP) from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"Full analysis set included all randomised participants. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Millimeters of mercury (mmHg)","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"198"}]}],"classes":[{"title":"sBP","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"188"},{"groupId":"OG001","value":"192"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6","spread":"14"},{"groupId":"OG001","value":"-2","spread":"15"}]}]},{"title":"dBP","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"188"},{"groupId":"OG001","value":"192"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3","spread":"9"},{"groupId":"OG001","value":"-1","spread":"9"}]}]}]},{"type":"SECONDARY","title":"Change in Lipids -Total Cholesterol, HDL, LDL, VLDL, Triglycerides and FFA","description":"Change in total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, very low density lipoprotein (VLDL) cholesterol, triglycerides and free fatty acids (FFA) from baseline (week 0) to week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"Full analysis set included all randomised participants. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"198"}]}],"classes":[{"title":"Total cholesterol","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"190"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.12","spread":"0.82"},{"groupId":"OG001","value":"0.04","spread":"0.69"}]}]},{"title":"HDL cholesterol","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"190"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.17"},{"groupId":"OG001","value":"0.03","spread":"0.17"}]}]},{"title":"LDL cholesterol","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"190"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"0.72"},{"groupId":"OG001","value":"0.05","spread":"0.57"}]}]},{"title":"VLDL cholesterol","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"190"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"0.35"},{"groupId":"OG001","value":"-0.04","spread":"0.33"}]}]},{"title":"Triglycerides","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"190"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.21","spread":"0.89"},{"groupId":"OG001","value":"-0.08","spread":"0.80"}]}]},{"title":"Free fatty acids","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"188"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.10","spread":"0.27"},{"groupId":"OG001","value":"-0.06","spread":"0.34"}]}]}]},{"type":"SECONDARY","title":"Change in SF-36: Sub-domains","description":"SF-36 is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in the sub-domain scores was presented based on in-trial data. A positive change score indicates an improvement since baseline. Results are presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"Full analysis set included all randomised participants. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Score on a scale","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"198"}]}],"classes":[{"title":"Bodily Pain","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"8.3"},{"groupId":"OG001","value":"1.2","spread":"9.1"}]}]},{"title":"General Health","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"7.8"},{"groupId":"OG001","value":"0.3","spread":"7.7"}]}]},{"title":"Physical Functioning","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"198"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"7.9"},{"groupId":"OG001","value":"2.6","spread":"7.3"}]}]},{"title":"Role-physical","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"7.7"},{"groupId":"OG001","value":"0.9","spread":"8.0"}]}]},{"title":"Role Lim Emotion Prob","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"8.1"},{"groupId":"OG001","value":"-0.3","spread":"8.2"}]}]},{"title":"Mental Health","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"8.6"},{"groupId":"OG001","value":"-1.1","spread":"7.5"}]}]},{"title":"Social Functioning","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"7.7"},{"groupId":"OG001","value":"-0.6","spread":"6.3"}]}]},{"title":"Vitality","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"8.0"},{"groupId":"OG001","value":"-0.0","spread":"7.7"}]}]}]},{"type":"SECONDARY","title":"Change in SF-36: Physical Component Summary (PCS)","description":"Change in short form 36 v2.0 acute domain physical component summary (PCS) from baseline (week 0) to week 56 was presented based on in-trial data. SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. It consists of 2 component summary measures that further summarize 8 health domain scales. The physical component summary (PCS) measure is derived from domain scales of physical functioning, role-physical, bodily pain, and general health. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. A positive change score indicates an improvement since baseline.","populationDescription":"Full analysis set included all randomised participants. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Score on a scale","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"198"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"7.5"},{"groupId":"OG001","value":"2.2","spread":"7.2"}]}]}]},{"type":"SECONDARY","title":"Change in SF-36: Mental Component Summary (MCS)","description":"Change in short form 36 v2.0 acute domain mental component summary (MCS) from baseline (week 0) to week 56 was presented based on in-trial data. SF- 36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The mental component summary (MCS) measure is derived from domain scales of vitality, social functioning, role emotional and mental health. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. A positive change score indicates an improvement since baseline.","populationDescription":"Full analysis set included all randomised participants. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Score on a scale","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"198"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"7.9"},{"groupId":"OG001","value":"-1.7","spread":"6.8"}]}]}]},{"type":"SECONDARY","title":"Change in IWQoL-Lite for CT: Pain/Discomfort Domain Score","description":"Change in IWQoL-Lite for CT pain and discomfort domain from baseline (week 0) to week 56 was presented based on in-trial data. IWQoL-Lite for CT is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"Full analysis set included all randomised participants. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Score on a scale","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"198"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"22.1"},{"groupId":"OG001","value":"4.6","spread":"23.1"}]}]}]},{"type":"SECONDARY","title":"Change in IWQoL-Lite for CT: Psychosocial Domain Score","description":"Change in IWQoL-Lite for CT psychosocial domain from baseline (week 0) to week 56 was presented based on in-trial data. IWQoL-Lite for CT is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"Full analysis set included all randomised participants. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Score on a scale","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"198"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":"18.4"},{"groupId":"OG001","value":"4.0","spread":"16.7"}]}]}]},{"type":"SECONDARY","title":"Change in IWQoL-Lite for CT: Total Score","description":"Change in IWQoL-Lite for CT total score from baseline (week 0) to week 56 was presented based on in-trial data. IWQoL-Lite for CT is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"Full analysis set included all randomised participants. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Score on a scale","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"198"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":"17.6"},{"groupId":"OG001","value":"4.8","spread":"16.6"}]}]}]},{"type":"SECONDARY","title":"Weight Related Sign and Symptom (WRSS) Measure, Categorical Responses","description":"The WRSS measure is a questionnaire under development. The version applied in this study has 10 items that measure the presence and bothersomeness of 10 weight-related symptoms. Each item has a categorical part with answers on the following 5 possible levels: 'Never/Almost never', 'Rarely', 'Sometimes', 'Often' and 'Almost always/Always'. Number of participants in each category at baseline (week 0) and week 56 was presented. Scoring algorithm was not available prior to database lock and therefore it was decided and documented in the statistical analysis plan that WRSS total score was not to be calculated and analyzed.","populationDescription":"Full analysis set included all randomised participants. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"198"}]}],"classes":[{"title":"Week 0: Joint pain","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"196"}]}],"categories":[{"title":"Almost always/Always","measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"5"}]},{"title":"Never/Almost never","measurements":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"85"}]},{"title":"Often","measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"18"}]},{"title":"Rarely","measurements":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"42"}]},{"title":"Sometimes","measurements":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"46"}]}]},{"title":"Week 56: Joint pain","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"188"}]}],"categories":[{"title":"Almost always/Always","measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"}]},{"title":"Never/Almost never","measurements":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"75"}]},{"title":"Often","measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"17"}]},{"title":"Rarely","measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"39"}]},{"title":"Sometimes","measurements":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"52"}]}]},{"title":"Week 0: Shortness of breath","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"196"}]}],"categories":[{"title":"Almost always/Always","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"Never/Almost never","measurements":[{"groupId":"OG000","value":"131"},{"groupId":"OG001","value":"140"}]},{"title":"Often","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]},{"title":"Rarely","measurements":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"32"}]},{"title":"Sometimes","measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"21"}]}]},{"title":"Week 56: Shortness of breath","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"188"}]}],"categories":[{"title":"Almost always/Always","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]},{"title":"Never/Almost never","measurements":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"111"}]},{"title":"Often","measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}]},{"title":"Rarely","measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"46"}]},{"title":"Sometimes","measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"27"}]}]},{"title":"Week 0: Heat sensitivity","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"196"}]}],"categories":[{"title":"Almost always/Always","measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}]},{"title":"Never/Almost never","measurements":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"109"}]},{"title":"Often","measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"16"}]},{"title":"Rarely","measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"31"}]},{"title":"Sometimes","measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"31"}]}]},{"title":"Week 56: Heat sensitivity","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"188"}]}],"categories":[{"title":"Almost always/Always","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"}]},{"title":"Never/Almost never","measurements":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"87"}]},{"title":"Often","measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"13"}]},{"title":"Rarely","measurements":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"47"}]},{"title":"Sometimes","measurements":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"33"}]}]},{"title":"Week 0: Sexual desire","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"196"}]}],"categories":[{"title":"Almost always/Always","measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"}]},{"title":"Never/Almost never","measurements":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"121"}]},{"title":"Often","measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"13"}]},{"title":"Rarely","measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"32"}]},{"title":"Sometimes","measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"22"}]}]},{"title":"Week 56: Sexual desire","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"188"}]}],"categories":[{"title":"Almost always/Always","measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"11"}]},{"title":"Never/Almost never","measurements":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"109"}]},{"title":"Often","measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"11"}]},{"title":"Rarely","measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"32"}]},{"title":"Sometimes","measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"25"}]}]},{"title":"Week 0: Heavy sweating","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"196"}]}],"categories":[{"title":"Almost always/Always","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"}]},{"title":"Never/Almost never","measurements":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"104"}]},{"title":"Often","measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"14"}]},{"title":"Rarely","measurements":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"38"}]},{"title":"Sometimes","measurements":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"35"}]}]},{"title":"Week 56: Heavy sweating","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"188"}]}],"categories":[{"title":"Almost always/Always","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"}]},{"title":"Never/Almost never","measurements":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"92"}]},{"title":"Often","measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"16"}]},{"title":"Rarely","measurements":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"48"}]},{"title":"Sometimes","measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"27"}]}]},{"title":"Week 0: Low physical stamina","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"196"}]}],"categories":[{"title":"Almost always/Always","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"}]},{"title":"Never/Almost never","measurements":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"78"}]},{"title":"Often","measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"14"}]},{"title":"Rarely","measurements":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"47"}]},{"title":"Sometimes","measurements":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"49"}]}]},{"title":"Week 56: Low physical stamina","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"188"}]}],"categories":[{"title":"Almost always/Always","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"}]},{"title":"Never/Almost never","measurements":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"65"}]},{"title":"Often","measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"19"}]},{"title":"Rarely","measurements":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"56"}]},{"title":"Sometimes","measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"44"}]}]},{"title":"Week 0: Foot pain","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"196"}]}],"categories":[{"title":"Almost always/Always","measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"7"}]},{"title":"Never/Almost never","measurements":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"108"}]},{"title":"Often","measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"}]},{"title":"Rarely","measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"31"}]},{"title":"Sometimes","measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"38"}]}]},{"title":"Week 56: Foot pain","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"188"}]}],"categories":[{"title":"Almost always/Always","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"7"}]},{"title":"Never/Almost never","measurements":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"88"}]},{"title":"Often","measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"14"}]},{"title":"Rarely","measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"39"}]},{"title":"Sometimes","measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"40"}]}]},{"title":"Week 0: Trouble sleeping","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"196"}]}],"categories":[{"title":"Almost always/Always","measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"}]},{"title":"Never/Almost never","measurements":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"111"}]},{"title":"Often","measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"10"}]},{"title":"Rarely","measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"42"}]},{"title":"Sometimes","measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"29"}]}]},{"title":"Week 56: Trouble sleeping","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"188"}]}],"categories":[{"title":"Almost always/Always","measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"}]},{"title":"Never/Almost never","measurements":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"98"}]},{"title":"Often","measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"14"}]},{"title":"Rarely","measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"33"}]},{"title":"Sometimes","measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"40"}]}]},{"title":"Week 0: Back pain","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"196"}]}],"categories":[{"title":"Almost always/Always","measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"6"}]},{"title":"Never/Almost never","measurements":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"98"}]},{"title":"Often","measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"8"}]},{"title":"Rarely","measurements":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"40"}]},{"title":"Sometimes","measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"44"}]}]},{"title":"Week 56: Back pain","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"188"}]}],"categories":[{"title":"Almost always/Always","measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"}]},{"title":"Never/Almost never","measurements":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"86"}]},{"title":"Often","measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"11"}]},{"title":"Rarely","measurements":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"45"}]},{"title":"Sometimes","measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"42"}]}]},{"title":"Week 0: Low energy","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"196"}]}],"categories":[{"title":"Almost always/Always","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]},{"title":"Never/Almost never","measurements":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"90"}]},{"title":"Often","measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"12"}]},{"title":"Rarely","measurements":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"42"}]},{"title":"Sometimes","measurements":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"50"}]}]},{"title":"Week 56: Low energy","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"188"}]}],"categories":[{"title":"Almost always/Always","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}]},{"title":"Never/Almost never","measurements":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"77"}]},{"title":"Often","measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"16"}]},{"title":"Rarely","measurements":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"50"}]},{"title":"Sometimes","measurements":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"41"}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieved (Yes/no): HbA1c <7% and Weight Loss ≥5%","description":"Percentage of participants who achieved HbA1c \\<7% and weight loss ≥5% from baseline at week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"Full analysis set included all randomised participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"198"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.9"},{"groupId":"OG001","value":"13.6"}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieved (Yes/no): HbA1c <7%, Weight Loss ≥5% and no Documented Symptomatic Hypoglycaemia","description":"Percentage of participants who achieved HbA1c \\<7%, weight loss ≥5% from baseline and no documented symptomatic hypoglycaemia at week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"Full analysis set included all randomised participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"198"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1"},{"groupId":"OG001","value":"3.5"}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieved (Yes/no): ≥4.3 T-score Points Increase From Baseline in SF-36 Acute Physical Functioning Score","description":"Percentage of participants who achieved ≥4.3 T-score points increase from baseline in SF-36 acute physical functioning score at week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"Full analysis set included all randomised participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"198"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.8"},{"groupId":"OG001","value":"26.3"}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieved (Yes/no): ≥3.8 T-score Points Increase From Baseline in SF-36 Acute PCS","description":"Percentage of participants who achieved ≥3.8 T-score points increase from baseline in SF-36 acute PCS at week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"Full analysis set included all randomised participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"198"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.9"},{"groupId":"OG001","value":"31.3"}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieved (Yes/no): ≥4.6 T-score Points Increase From Baseline in SF-36 Acute MCS","description":"Percentage of participants who achieved ≥4.6 T-score points increase from baseline in SF-36 acute MCS at week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"Full analysis set included all randomised participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"198"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.6"},{"groupId":"OG001","value":"11.6"}]}]}]},{"type":"SECONDARY","title":"Responder Definition Value for IWQoL-Lite for CT Physical Function Domain Score","description":"Percentage of participants who achieve responder definition value for IWQoL-Lite for CT physical function domain score was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"Full analysis set included all randomised participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"198"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.3"},{"groupId":"OG001","value":"24.2"}]}]}]},{"type":"SECONDARY","title":"Adverse Events (AEs)","description":"An AE was defined as any untoward medical occurrence in a participant administered a medicinal product, and which does not necessarily have a causal relationship with this treatment. Number of AEs from randomisation to until the end of the post-treatment follow-up period (30 days). Results based on in-trial data was presented. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"Safety analysis set (SAS) included all randomised participants exposed to at least one dose of trial drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Adverse events","timeFrame":"Week 0 to week 56 + 30 days","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1223"},{"groupId":"OG001","value":"1148"}]}]}]},{"type":"SECONDARY","title":"Number of Hypoglycaemic Episodes","description":"Number of hypoglycaemic episodes was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"SAS included all randomised participants exposed to at least one dose of trial drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Hypoglycaemic episodes","timeFrame":"Week 0 to week 56 + 30 days","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1538"},{"groupId":"OG001","value":"1973"}]}]}]},{"type":"SECONDARY","title":"Change in Physical Examination","description":"Physical examination parameters are categorised as abdomen; gastrointestinal system; cardiovascular system; central and peripheral nervous system; general appearance; head, eyes, ears, nose, throat (ENT) and neck; lymph node palpation; musculoskeletal system; respiratory system; skin and thyroid gland. The number of participants assessed as normal, abnormal not clinically significant (NCS) and abnormal clinically significant (CS) at baseline (week -1) and week 56 was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"SAS included all randomised participants exposed to at least one dose of trial drug. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Week -1, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"classes":[{"title":"Abdomen (week -1) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"169"}]}]},{"title":"Abdomen (week -1) Abnormal, NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"25"}]}]},{"title":"Abdomen (week -1) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}]}]},{"title":"Abdomen (week 56) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"167"},{"groupId":"OG001","value":"160"}]}]},{"title":"Abdomen (week 56) Abnormal, NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"24"}]}]},{"title":"Abdomen (week 56) Abnormal, CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}]},{"title":"Gastrointestinal System (week -1) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}]},{"title":"Gastrointestinal System (week -1) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"}]}]},{"title":"Gastrointestinal System (week -1) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Gastrointestinal System (week 56) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"185"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"177"}]}]},{"title":"Gastrointestinal System (week 56) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"185"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"8"}]}]},{"title":"Gastrointestinal System (week 56) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"185"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Cardiovascular System (week-1) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"182"}]}]},{"title":"Cardiovascular System (week-1) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"15"}]}]},{"title":"Cardiovascular System (week-1) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Cardiovascular System (week 56) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"178"},{"groupId":"OG001","value":"175"}]}]},{"title":"Cardiovascular System (week 56) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"12"}]}]},{"title":"Cardiovascular System (week 56) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Nervous System (week -1) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"159"}]}]},{"title":"Nervous System (week -1) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"25"}]}]},{"title":"Nervous System (week -1) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"13"}]}]},{"title":"Nervous System (week 56) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"150"},{"groupId":"OG001","value":"149"}]}]},{"title":"Nervous System (week 56) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"24"}]}]},{"title":"Nervous System (week 56) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"14"}]}]},{"title":"General Appearance (week -1) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"150"},{"groupId":"OG001","value":"150"}]}]},{"title":"General Appearance (week -1) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"36"}]}]},{"title":"General Appearance (week -1) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"11"}]}]},{"title":"General Appearance (week 56) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"151"}]}]},{"title":"General Appearance (week 56) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"27"}]}]},{"title":"General Appearance (week 56) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"}]}]},{"title":"Head, eyes, ENTand Neck (week -1) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"176"},{"groupId":"OG001","value":"182"}]}]},{"title":"Head, eyes, ENTand Neck (week -1) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"13"}]}]},{"title":"Head, eyes, ENTand Neck (week -1) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]},{"title":"Head, eyes, ENTand Neck (week 56) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"168"},{"groupId":"OG001","value":"173"}]}]},{"title":"Head, eyes, ENTand Neck (week 56) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"12"}]}]},{"title":"Head, eyes, ENTand Neck (week 56) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]},{"title":"Lymph Node Palpation (week -1) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}]},{"title":"Lymph Node Palpation (week -1) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Lymph Node Palpation (week -1) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Lymph Node Palpation (week 56) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"186"}]}]},{"title":"Lymph Node Palpation (week 56) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Lymph Node Palpation (week 56) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Musculoskeletal System (week -1) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"180"}]}]},{"title":"Musculoskeletal System (week -1) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"16"}]}]},{"title":"Musculoskeletal System (week -1) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"Musculoskeletal System (week 56) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"171"}]}]},{"title":"Musculoskeletal System (week 56) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"14"}]}]},{"title":"Musculoskeletal System (week 56) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]},{"title":"Respiratory System (week -1) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"192"},{"groupId":"OG001","value":"192"}]}]},{"title":"Respiratory System (week -1) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}]},{"title":"Respiratory System (week -1) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"Respiratory System (week 56) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"185"}]}]},{"title":"Respiratory System (week 56) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Respiratory System (week 56) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"Skin (week -1) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"155"},{"groupId":"OG001","value":"156"}]}]},{"title":"Skin (week -1) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"33"}]}]},{"title":"Skin (week -1) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"8"}]}]},{"title":"Skin (week 56) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"150"},{"groupId":"OG001","value":"149"}]}]},{"title":"Skin (week 56) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"29"}]}]},{"title":"Skin (week 56) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"}]}]},{"title":"Thyroid Gland (week -1) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"187"}]}]},{"title":"Thyroid Gland (week -1) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"}]}]},{"title":"Thyroid Gland (week -1) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}]},{"title":"Thyroid Gland (week 56) Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"178"}]}]},{"title":"Thyroid Gland (week 56) Abnormal NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"}]}]},{"title":"Thyroid Gland (week 56) Abnormal CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"187"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}]}]},{"type":"SECONDARY","title":"Change in Resting Pulse","description":"Change from baseline (week -1) to week 56 in resting pulse was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"SAS included all randomised participants exposed to at least one dose of trial drug. \"Number analyzed\" = participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Beats/minute","timeFrame":"Week -1, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":"9"},{"groupId":"OG001","value":"-0","spread":"9"}]}]}]},{"type":"SECONDARY","title":"Change in Electrocardiogram (ECG)","description":"The ECGs were interpreted by the investigator at baseline (week -1) and week 56 and categorised as normal, abnormal NCS or abnormal CS. Number of participants in each ECG category at baseline and week 56 were presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"SAS included all randomised participants exposed to at least one dose of trial drug. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Week -1, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"classes":[{"title":"Normal (week -1)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"133"}]}]},{"title":"Abnormal NCS (week -1)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"60"}]}]},{"title":"Abnormal CS (week -1)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}]}]},{"title":"Normal (week 56)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"126"}]}]},{"title":"Abnormal NCS (week 56)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"57"}]}]},{"title":"Abnormal CS (week 56)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}]}]}]},{"type":"SECONDARY","title":"Change in Laboratory Measurements (Haematology) - Haemoglobin","description":"Change from baseline (week 0) to week 56 in haemoglobin was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"SAS included all randomised participants exposed to at least one dose of trial drug. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.5"},{"groupId":"OG001","value":"-0.1","spread":"0.6"}]}]}]},{"type":"SECONDARY","title":"Change in Laboratory Measurements (Haematology) - Haematocrit","description":"Change from baseline (week 0) to week 56 in Haematocrit was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"SAS included all randomised participants exposed to at least one dose of trial drug. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percentage of red blood cells","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"2.8"},{"groupId":"OG001","value":"-0.2","spread":"3.0"}]}]}]},{"type":"SECONDARY","title":"Change in Laboratory Measurements (Haematology) - Erythrocytes","description":"Change from baseline (week 0) to week 56 in erythrocytes was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"SAS included all randomised participants exposed to at least one dose of trial drug. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^12 cells per liter (10^12 cells/L)","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","spread":"0.27"},{"groupId":"OG001","value":"-0.04","spread":"0.28"}]}]}]},{"type":"SECONDARY","title":"Change in Laboratory Measurements (Haematology) - Thrombocytes, Leukocytes","description":"Change from baseline (week 0) to week 56 in thrombocytes and leukocytes was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"SAS included all randomised participants exposed to at least one dose of trial drug. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^9 cells/L","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"classes":[{"title":"Thrombocytes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":"45"},{"groupId":"OG001","value":"7","spread":"46"}]}]},{"title":"Leukocytes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"186"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.22","spread":"1.41"},{"groupId":"OG001","value":"-0.24","spread":"1.28"}]}]}]},{"type":"SECONDARY","title":"Change in Laboratory Parameters (Biochemistry) - Albumin","description":"Change from baseline (week 0) to week 56 in albumin was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"SAS included all randomised participants exposed to at least one dose of trial drug. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Grams per deciliter (g/dL)","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.2"},{"groupId":"OG001","value":"-0.1","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Change in Laboratory Parameters (Biochemistry) - Alkaline Phosphatase, Alanine Aminotransferase, Amylase, Aspartate Aminotransferase and Lipase","description":"Change from baseline (week 0) to week 56 in alkaline phosphatase, alanine aminotransferase, amylase, aspartate aminotransferase and lipase was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"SAS included all randomised participants exposed to at least one dose of trial drug. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Units per liter (U/L)","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"classes":[{"title":"Alkaline Phosphatase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"189"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1","spread":"16"},{"groupId":"OG001","value":"-0","spread":"15"}]}]},{"title":"Alanine Aminotransferase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"188"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5","spread":"15"},{"groupId":"OG001","value":"-6","spread":"18"}]}]},{"title":"Amylase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"189"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":"73"},{"groupId":"OG001","value":"-1","spread":"22"}]}]},{"title":"Aspartate aminotransferase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"189"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3","spread":"11"},{"groupId":"OG001","value":"-3","spread":"14"}]}]},{"title":"Lipase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"189"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":"143"},{"groupId":"OG001","value":"-8","spread":"47"}]}]}]},{"type":"SECONDARY","title":"Change in Laboratory Parameters (Biochemistry) - Bicarbonate, Total Calcium, Potassium, Sodium and Urea","description":"Change from baseline (week 0) to week 56 in bicarbonate, total calcium, potassium, sodium and urea was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"SAS included all randomised participants exposed to at least one dose of trial drug. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"classes":[{"title":"Bicarbonate serum","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"171"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"2"},{"groupId":"OG001","value":"-0","spread":"2"}]}]},{"title":"Total Calcium","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"189"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.00","spread":"0.11"},{"groupId":"OG001","value":"-0.02","spread":"0.14"}]}]},{"title":"Potassium","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"189"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.5"},{"groupId":"OG001","value":"-0.0","spread":"0.5"}]}]},{"title":"Sodium","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"189"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1","spread":"2"},{"groupId":"OG001","value":"-0","spread":"3"}]}]},{"title":"Urea","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"189"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.5"},{"groupId":"OG001","value":"0.1","spread":"1.4"}]}]}]},{"type":"SECONDARY","title":"Change in Laboratory Parameters (Biochemistry) - Total Bilirubin and Creatinine","description":"Change from baseline (week 0) to week 56 in total bilirubin and creatinine was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"SAS included all randomised participants exposed to at least one dose of trial drug. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Micromoles per liter (umol/L)","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"classes":[{"title":"Total Bilirubin","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"188"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"3.9"},{"groupId":"OG001","value":"0.6","spread":"3.6"}]}]},{"title":"Creatinine","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"189"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"8.7"},{"groupId":"OG001","value":"-0.2","spread":"8.4"}]}]}]},{"type":"SECONDARY","title":"Change in Laboratory Parameters (Biochemistry) - High Sensitive C-reactive Protein","description":"Change from baseline (week 0) to week 56 in high sensitive C-reactive protein was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"SAS included all randomised participants exposed to at least one dose of trial drug. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Milligrams per liter (mg/L)","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.40","spread":"8.02"},{"groupId":"OG001","value":"-1.29","spread":"10.07"}]}]}]},{"type":"SECONDARY","title":"Change in Laboratory Parameters (Biochemistry) - eGFR","description":"Change from baseline (week 0) to week 56 in estimated GFR serum using Modification of Diet in Renal Disease (MDRD) formula was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"SAS included all randomised participants exposed to at least one dose of trial drug. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Milliliters per minute per 1.73m^2","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"13"},{"groupId":"OG001","value":"1","spread":"13"}]}]}]},{"type":"SECONDARY","title":"Change in Laboratory Parameters (Biochemistry) - Uric Acid","description":"Change from baseline (week 0) to week 56 in uric acid was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"SAS included all randomised participants exposed to at least one dose of trial drug. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mg/dL","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"1.0"},{"groupId":"OG001","value":"-0.0","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Change in Laboratory Parameters (Biochemistry) - Calcitonin","description":"Change from baseline (week 0) to week 56 in calcitonin was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"SAS included all randomised participants exposed to at least one dose of trial drug. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Nanograms per liter (ng/L)","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"1.5"},{"groupId":"OG001","value":"0.0","spread":"1.4"}]}]}]},{"type":"SECONDARY","title":"Change in Laboratory Parameters (Biochemistry) - Thyroid Stimulating Hormone","description":"Change from baseline (week 0) to week 56 in thyroid stimulating hormone was presented based on in-trial data. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact.","populationDescription":"SAS included all randomised participants exposed to at least one dose of trial drug. \"Number analyzed\"=participants with available data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Milli-international units per liter","timeFrame":"Week 0, week 56","groups":[{"id":"OG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"197"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0842","spread":"1.2233"},{"groupId":"OG001","value":"0.1002","spread":"0.9493"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From the date of first dose of trial product (week 0) to end of treatment (week 56) + post treatment follow-up of 30 days.","description":"Evaluation of safety was based on SAS which comprised of all randomised participants who received at least one dose of trial product.\n\nAEs with onset during the on-treatment observation period (the period when participants were exposed to trial product) were considered treatment-emergent.","eventGroups":[{"id":"EG000","title":"Liraglutide 3.0 mg","description":"Participants received liraglutide once daily by subcutaneous injection irrespective of the timing of meals. Participants received 0.6 mg liraglutide during the first week. The dose was escalated in weekly increments of 0.6 mg until the maintenance dose of 3.0 mg was reached after 4 weeks. The treatment period was 56 weeks.","deathsNumAffected":0,"deathsNumAtRisk":195,"seriousNumAffected":16,"seriousNumAtRisk":195,"otherNumAffected":162,"otherNumAtRisk":195},{"id":"EG001","title":"Placebo","description":"Participants received matching placebo once daily by subcutaneous injection irrespective of the timing of meals. Dose escalation for placebo matched that of liraglutide. The treatment period was 56 weeks.","deathsNumAffected":0,"deathsNumAtRisk":197,"seriousNumAffected":19,"seriousNumAtRisk":197,"otherNumAffected":141,"otherNumAtRisk":197}],"seriousEvents":[{"term":"Adenocarcinoma pancreas","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":195},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":197}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":195},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":197}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":195},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":197}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":195},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":197}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":195},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":197}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":195},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":197}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":195},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":197}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":195},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":197}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":195},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":197}]},{"term":"Diverticulum","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":195},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":197}]},{"term":"Duodenal ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":195},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":197}]},{"term":"Endometrial hyperplasia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":195},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":197}]},{"term":"Escherichia bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":195},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":197}]},{"term":"Facial bones fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":195},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":197}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":195},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":197}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":195},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":197}]},{"term":"Haemorrhage intracranial","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":195},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":197}]},{"term":"Hand fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":195},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":197}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":195},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":197}]},{"term":"Intervertebral disc disorder","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":195},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":197}]},{"term":"Invasive lobular breast carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":195},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":197}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":195},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":197}]},{"term":"Lipoma excision","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":195},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":197}]},{"term":"Malignant melanoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":195},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":197}]},{"term":"Meniscus injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":195},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":197}]},{"term":"Metaphyseal corner fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":195},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":197}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":195},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":197}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":195},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":197}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":195},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":197}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":195},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":197}]},{"term":"Peptic ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":195},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":197}]},{"term":"Peripheral vascular disorder","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":195},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":197}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":195},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":197}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":195},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":197}]},{"term":"Postpericardiotomy syndrome","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":195},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":197}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":195},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":197}]},{"term":"Relapsing-remitting multiple sclerosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":195},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":197}]},{"term":"Renal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":195},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":197}]},{"term":"Spinal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":195},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":197}]},{"term":"Subdural haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":195},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":197}]},{"term":"Thyroid adenoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":195},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":197}]},{"term":"Ureterolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":195},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":197}]},{"term":"Urinary incontinence","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":195},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":197}]},{"term":"Urinary retention postoperative","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":195},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":197}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":195},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":197}]},{"term":"Wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":195},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":197}]}],"otherEvents":[{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":11,"numAtRisk":195},{"groupId":"EG001","numEvents":11,"numAffected":8,"numAtRisk":197}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":12,"numAtRisk":195},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":197}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":12,"numAtRisk":195},{"groupId":"EG001","numEvents":37,"numAffected":24,"numAtRisk":197}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":13,"numAtRisk":195},{"groupId":"EG001","numEvents":17,"numAffected":12,"numAtRisk":197}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":36,"numAffected":28,"numAtRisk":195},{"groupId":"EG001","numEvents":21,"numAffected":17,"numAtRisk":197}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":19,"numAtRisk":195},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":197}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":77,"numAffected":45,"numAtRisk":195},{"groupId":"EG001","numEvents":54,"numAffected":30,"numAtRisk":197}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":13,"numAtRisk":195},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":197}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":12,"numAtRisk":195},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":197}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":14,"numAtRisk":195},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":197}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":15,"numAtRisk":195},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":197}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":10,"numAtRisk":195},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":197}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":36,"numAffected":29,"numAtRisk":195},{"groupId":"EG001","numEvents":47,"numAffected":29,"numAtRisk":197}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":195},{"groupId":"EG001","numEvents":14,"numAffected":12,"numAtRisk":197}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":12,"numAtRisk":195},{"groupId":"EG001","numEvents":26,"numAffected":22,"numAtRisk":197}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":48,"numAffected":42,"numAtRisk":195},{"groupId":"EG001","numEvents":49,"numAffected":36,"numAtRisk":197}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":105,"numAffected":58,"numAtRisk":195},{"groupId":"EG001","numEvents":27,"numAffected":23,"numAtRisk":197}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":195},{"groupId":"EG001","numEvents":12,"numAffected":10,"numAtRisk":197}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":6,"numAtRisk":195},{"groupId":"EG001","numEvents":13,"numAffected":12,"numAtRisk":197}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":16,"numAtRisk":195},{"groupId":"EG001","numEvents":21,"numAffected":19,"numAtRisk":197}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":9,"numAtRisk":195},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":197}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":32,"numAffected":24,"numAtRisk":195},{"groupId":"EG001","numEvents":37,"numAffected":29,"numAtRisk":197}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":7,"numAtRisk":195},{"groupId":"EG001","numEvents":22,"numAffected":19,"numAtRisk":197}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":53,"numAffected":32,"numAtRisk":195},{"groupId":"EG001","numEvents":13,"numAffected":12,"numAtRisk":197}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property."},"pointOfContact":{"title":"Clinical Reporting Anchor and Disclosure (1452)","organization":"Novo Nordisk A/S","email":"clinicaltrials@novonordisk.com","phone":"(+1) 866-867-7178"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2019-02-18","uploadDate":"2019-09-04T02:14","filename":"Prot_000.pdf","size":1776538},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2019-02-18","uploadDate":"2019-09-04T02:14","filename":"SAP_001.pdf","size":960446}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"conditionBrowseModule":{"meshes":[{"id":"D009748","term":"Nutrition Disorders"},{"id":"D009765","term":"Obesity"}],"ancestors":[{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D050177","term":"Overweight"},{"id":"D044343","term":"Overnutrition"},{"id":"D001835","term":"Body Weight"},{"id":"D012816","term":"Signs and Symptoms"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069450","term":"Liraglutide"}],"ancestors":[{"id":"D052216","term":"Glucagon-Like Peptide 1"},{"id":"D004763","term":"Glucagon-Like Peptides"},{"id":"D052336","term":"Proglucagon"},{"id":"D005768","term":"Gastrointestinal Hormones"},{"id":"D006728","term":"Hormones"},{"id":"D006730","term":"Hormones, Hormone Substitutes, and Hormone Antagonists"}]}},"hasResults":true}